[View Larger Version of this Image]

Figure S2. Biophysical characterization of purified WT- and MI-FSAP. (A) WT- or MI-FSAP (50 ng/ lane) was activated with heparin (10 µg/ml) for the indicated times, loaded on SDS-PAGE under reducing conditions, analyzed by Western blotting with an anti-heavy chain FSAP antibody (top) or an anti-light chain FSAP antibody (bottom). (B) WT- or MI-FSAP was digested with chymotrypsin, and the derivatised peptides were analyzed by MALDI-TOF mass spectrometry (Bruker Ultraflex MALDI TOF/TOF). The predicted sequences and MW of WT- and MI-FSAP peptide (530-540) are indicated.